Quality by Design for Analytical Methods: Implications for Method Validation and Transfer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Quality by Design for Analytical Methods: Implications for Method Validation and Transfer
The authors describe how traditional approaches to analytical method and validation may benefit from alignment with quality-by-design concepts.

Pharmaceutical Technology
Volume 36, Issue 10, pp. 74-79


1. P. Nethercote, et al., "QbD for Better Method Validation and Transfer," Pharmamanuf. online, http://www.pharmamanufacturing.com/articles/2010/060.html, accessed June 10, 2012.

2. FDA, Pharmaceutical cGMPs for the 21st Century—A Risk-Based Approach (Rockville, MD, 2004).

3. FDA, Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Jan. 2011).

4. M. Nasr, presentation at the AAPS Workshop (North Bethesda, MD, Oct. 5, 2005).

5. ICH, Q2(R1), Validation of Analytical Procedures: Text and Methodology, Step 4 version (2005).

6. P. Borman, et al., Pharm. Tech., 31 (10), 142–152 (2007).

7. USP General Chapter <1058>, "Analytical Instrument Qualification."

8. J. Ermer and J.S. Landy, "Validation of analytical procedures," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan, Eds. (Dekker, New York, 2nd ed., 2002), pp. 507–528.

9. ICH, Q8, Pharmaceutical Development (2009).

10. M. Schweitzer, et al., Pharm. Tech., 34(2), 52–59 (2010).

11. P.J. Borman, et al., Anal. Chim. Acta., 703(2), 101–113 (2011).

12. J. Ermer, et al., J. Pharm. Biomed. Anal., 38(4) 653–663 (2005).

13. USP General Chapter <1010>, "Analytical Data Interpretation & Treatment."

14. ICH, Q9, Quality Risk Management (2005).

15. ICH, Q10, Pharmaceutical Quality System (2008).

16. E. Ciurczak, "ICH Guidances (Already) Show Their Age," http://www.pharmamanufacturing.com/articles/2008/158.html, accessed June 10, 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here